

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office on the date shown below:

RESPONSE UNDER 37 CFR §1.111
Examining Group 1617
Patent Application
Docket No. GJE-6758

September 20, 2007

David R. Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Layla Soroush
Art Unit : 1617
Applicant : David Cavalla, Robert William Gristwood
Serial No. : 10/519,594
Conf. No. : 2624
Filed : December 28, 2004
For : 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)
Pyrimidine in the Treatment of Functional Bowel Disorder

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

RESPONSE UNDER 37 CFR §1.111

Sir:

A Petition and Fee for an Extension of Time is being authorized with the electronic filing of this paper.

In response to the Office Action dated May 31, 2007, the following remarks are respectfully presented.

Remarks/Arguments follow the amendment sections of this paper.